Navidea Biopharmaceuticals, Inc. announced that it has entered into a Stock Purchase Agreement with two accredited investors pursuant to which the company agreed to issue a private placement a total of 11,000 shares of Series J convertible preferred stock at a price of $100 per share for the gross proceeds of $1,100,000 on May 22, 2023.The Company also agreed to provide the investors with certain registration rights related to the resale of the shares of the company's common stock, par value $0.001 per share issuable upon conversion of the Series J preferred stock.